Research

Building Brain Metastasis Framework Studying Glioblastoma's (GBM) Trial Failures

Every GBM trial failure carries a failure signature — a specific combination of target validity, delivery architecture, patient selection, a…

Part 2 — NCT02264678 CAPRI: Ceralasertib + Olaparib and the BRCA resistance problem.

Trial: NCT02264678 (CAPRI) Drugs: Ceralasertib (ATRi) + Olaparib (PARPi) Cancer: Recurrent high-grade serous ovarian carcinoma (HGSOC) Publi…

Part 1: Adavosertib — NCT03579316 (CrisPRO, WEE1, and PTEN Loss)

Trial: NCT03579316 Drug: Adavosertib (AZD1775) — WEE1 kinase inhibitor Combination: + Gemcitabine Cancer: Recurrent/refractory solid tumors…

MBD4 deficiency defines a BER-defective state characterized by cytidine-analog synthetic lethality, replication stress-driven ATR checkpoint dependency, and falsification of a transcriptional PARP1-upregulation model for PARP-trapping vulnerability

Mechanism-Based Trial Matching Reveals a 54% Target Alignment Gap in Ovarian Cancer: Quantifying the Precision-Ineligible Majority

Stage-aware CRISPR design for brain metastasis interception: Multi-modal 'in-silico' framework of BBB extravasation and CNS colonization targets

capri

Trial Blog 01 — NCT03579316 Adavosertib (WEE1i): CrisPRO's strongest retroactive validation. Delta 0.307.

Abstract LB340: Mechanism-based trial matching reveals a 54% target alignment gap in ovarian cancer: Quantifying the precision-eligible ovarian cancer patients

F Kiani

Intercepting metastasis: 8-step CRISPR design via multi-modal foundation models.

F Kiani

Abstract B065: Stage-aware CRISPR design for brain metastasis interception: Multi-modal validation of BBB extravasation and CNS colonization targets

F Kiani, SA Allah